~ 1 billion USD
Invested each year in scientific research
People with a passion for science
Post docs globally
Publications in scientific journals annually
Leading scientific capabilities
Translational science & biology
Our bioscience groups are accountable for testing biological hypotheses by using in vitro and in vivo assays and innovative disease models. Our teams excel in the analysis of disease tissue and the application of bio-informatic approaches to support the identification and validation of targets regulating biological processes. We run an active post doc programme, pursuing blues skies research to help improve our understanding of disease. Our translational expertise enables us to accelerate the development of new druggable targets in human disease and select the right patients in early clinical trials. Our Early Clinical Development team specialises in interpreted quantitative data analysis developed using the latest, model-based drug development techniques and technologies.
Our medicinal chemistry capabilities enable us to integrate structural, pharmacological, pharmacokinetic and toxicological information to support the innovative design of novel chemical compounds. Pushing the boundaries of medicinal chemistry enables the delivery of new candidate drugs into our pipeline and is the foundation of small molecule drug discovery across the company. We also work on next-generation devices and delivery through our pharmaceutical development group.
Our leading High Throughput Screening capabilities ensure we can develop and deliver novel reagents and high quality assays to support efficient and effective pre-clinical drug discovery and biomarker development in later clinical phases. In parallel to this, we use our screening capabilities to provide project teams with mechanism of action, biology, safety and drug metabolism and pharmacokinetics (DMPK) insights across lead generation and lead optimisation projects, while our structure and biophysics group use protein structure and biophysics to understand the relationships between target protein and chemical space.
As a leader in personalised healthcare, we are committed to matching new medicines to the patients most in need. We combine industry-leading expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers, working collaboratively with our external partners to harness break-through technologies across the life-cycle of our medicines.
Our Early Clinical Development team designs and delivers early phase development strategies and exploratory studies that build the credentials of novel targets. Clinical Operations delivers global clinical trials for late stage projects across our pipeline, using both internal and external programme and study management expertise. Our leading expertise in large outcomes trials enables us to deliver multi-country, multi-site studies with thousands of patients, many of which include a personalised approach.
Drug safety and metabolism
We apply our drug metabolism and pharmacokinetics (DMPK) expertise to deliver in vitro and in vivo data, mass spectrometry imaging data, expertise and isotopically labelled compounds to our project teams. By following the science and combining our expertise with that of our external partners, our teams accelerate the discovery and development of safe, new medicines across our focus areas. We also apply our discovery safety expertise to deliver in silico, in vitro and in vivo data for target and chemical risk assessments and deliver quantitative translational safety models for functional and pathological safety signals.
"I am excited about our work in cardiac regeneration – the focus on using cells derived from patients and the use of phenotypic screening will allow us to identify both novel and biologically relevant compounds that could help patients in the future."
Inspiring the next generation
We believe that in order to continue discovering and developing life-changing medicines, we must also continue to inspire the next generation of ground-breaking scientists.
Explore current opportunities
Vibrant science centres
With four research centres across three continents, we know that vibrant and open science centres are a vital part of sustainable innovation.
Open for innovation
What our partners say
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
projects in our pipeline
new molecular entity approval in the last quarter
new molecular entities in our late-stage pipeline
Commitment to science
Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.
C/EBP-Homologous Protein (CHOP) in Vascular Smooth Muscle Cells Regulates Their Proliferation in Aortic Explants and Atherosclerotic Lesions
Published: 8 November 2014.
AstraZeneca/MedImmune author: Alex-Xianghua Zhou
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress
Published: 12 January 2015
KCC2 activity is critical in limiting the onset and severity of status epilepticus
Published: 2 March 2015
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.